ESSA Pharma - ADR Peer Comparison
$0.20
$0.00
(-0.10%)
As on 09-Oct-2025 09:30EDT
Market cap
$10 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
87.6 %
Edit
| ESSA Pharma - ADR | Xenon Pharmaceuticals (XENE) | Aurinia Pharmaceuticals (AUPH) | Abcellera Biologics Inc (ABCL) | DiaMedica Therapeutics (DMAC) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
10 | 5,885 | 2,215 | 3,668 | 352 |
Revenue ($ Mln) |
0 | -- | 312 | 66 | 0 |
Net Profit ($ Mln) |
-25.27 | -409.20 | 314.11 | -164.66 | -37.54 |
Net Margin (%) |
-18,611.02 | -- | 100.84 | -248.83 | 134,079.79 |
RoE (%) |
-22.19 | -44.86 | 52.52 | -17.68 | -79.49 |
Price to Earnings |
-- | -- | 7.30 | -- | -- |
Price-To-Book |
0.09 | 4.66 | 3.74 | 4.18 | 9.16 |
Cashflow ($ Mln)
| ESSA Pharma - ADR | Xenon Pharmaceuticals (XENE) | Aurinia Pharmaceuticals (AUPH) | Abcellera Biologics Inc (ABCL) | DiaMedica Therapeutics (DMAC) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-22.72 | -181.39 | 44.39 | -108.56 | -22.08 |
|
Cash Flow from Investing Activities
|
91.79 | 165.00 | 39.26 | 121.41 | 8.56 |
|
Cash from Financing Activities
|
0.93 | 12.13 | -49.09 | 12.77 | 11.99 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| ESSA Pharma - ADR | Xenon Pharmaceuticals (XENE) | Aurinia Pharmaceuticals (AUPH) | Abcellera Biologics Inc (ABCL) | DiaMedica Therapeutics (DMAC) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-21.09 | -27.52 | 1.23 | -13.85 | -52.84 |
|
ROE (%)
|
-22.19 | -27.85 | 1.52 | -14.75 | -53.27 |
|
ROA (%)
|
-20.35 | -26.58 | 1.05 | -11.43 | -48.64 |
|
EBIT Margin (%)
|
-20,363.00 | -- | -- | -- | -- |
|
Net Margin (%)
|
-18,611.02 | -- | 2.45 | -564.83 | -- |
|
Cash Profit Margin (%)
|
-0.21 | -- | -- | -- | -- |
Growth Ratios
| ESSA Pharma - ADR | Xenon Pharmaceuticals (XENE) | Aurinia Pharmaceuticals (AUPH) | Abcellera Biologics Inc (ABCL) | DiaMedica Therapeutics (DMAC) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -1.00 | 0.34 | -0.24 | -- |
|
EBIT Growth (%)
|
0.09 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
8.69 | -28.48 | 107.37 | -11.24 | -26.12 |
|
EPS Growth (%)
|
9.01 | -0.15 | 1.07 | -0.10 | -0.12 |
|
Book Value Growth (%)
|
-15.53 | -- | -- | -- | -- |
Valuation Ratios
| ESSA Pharma - ADR | Xenon Pharmaceuticals (XENE) | Aurinia Pharmaceuticals (AUPH) | Abcellera Biologics Inc (ABCL) | DiaMedica Therapeutics (DMAC) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-9.42 | -13.11 | 230.55 | -5.30 | -9.51 |
|
Price / Book Value
|
2.16 | 4.07 | 3.51 | 0.82 | 5.71 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-5.01 | -10.41 | 33.00 | -1.48 | -7.74 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| ESSA Pharma - ADR | Xenon Pharmaceuticals (XENE) | Aurinia Pharmaceuticals (AUPH) | Abcellera Biologics Inc (ABCL) | DiaMedica Therapeutics (DMAC) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.01 | 0.21 | 0.06 | 0.01 |
|
Short term debt to equity ratio
|
0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
|
Current Ratio
|
69.07 | 17.85 | 4.57 | 9.81 | 8.28 |
|
Quick Ratio
|
69.07 | 23.65 | 4.17 | 9.81 | -- |
|
Interest Coverage
|
-- | -- | 2.54 | -- | -- |
Operating Efficiency Ratios
| ESSA Pharma - ADR | Xenon Pharmaceuticals (XENE) | Aurinia Pharmaceuticals (AUPH) | Abcellera Biologics Inc (ABCL) | DiaMedica Therapeutics (DMAC) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
388.31 | -- | 15.54 | 319.53 | -- |
|
Asset Turnover
|
0.00 | 0.00 | 0.43 | 0.02 | 0.00 |
|
Receivable days
|
-- | -- | 47.09 | 991.33 | -- |
|
Inventory Days
|
-- | 0.00 | 510.31 | 2.08 | -- |
|
Payable days
|
8,925.29 | 975.05 | 61.51 | 112.70 | 8,737.90 |
|
Cash Conversion Cycle
|
-- | -- | 495.89 | 880.71 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
